Impact of vaccine-induced mucosal high-avidity CD8+CTLs in delay of AIDS viral dissemination from mucosa

Blood

Volumn 107, Issue 8, 2006, Pages 3258-3264

  Belyakov, Igor M ^a   Kuznetsov, Vladimir A ^b   Kelsall, Brian ^b   Klinman, Dennis ^b   Moniuszko, Marcin ^b   Lemon, Michael ^b   Markham, Phillip D ^b   Pal, Ranajit ^b   Clements, John D ^b   Lewis, Mark G ^b   Strober, Warren ^b   Franchini, Genoveffa ^b   Berzofsky, Jay A ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; ESCHERICHIA COLI PROTEIN; GAG PROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 12; PEPTIDE DERIVATIVE; POL PROTEIN; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; TRANSACTIVATOR PROTEIN; VIF PROTEIN; VIRUS ENVELOPE PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; MACACA; MUCOSA; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION; VIREMIA; VIRUS IMMUNITY; VIRUS TRANSMISSION;

EID: 33645748846     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-11-4374     Document Type: Article

References (56)

1. + T cell depletion and viral replication in SIV infection. Science. 1998;280:427-431.
2. + T cells. Science. 1999;286:1353-1357.
3. + T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med. 2004;200:749-759.
4. + T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med. 2004;200:761-770.
5. + cytotoxic T lymphocytes for resistance to mucosal-viral transmission in mice and enhancement of resistance by local administration of IL-12. J Clin Invest. 1998;102:2072-2081.
6. Belyakov IM, Derby MA, Ahlers JD, et al. Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. Proc Natl Acad Sci U S A. 1998;95:1709-1714.
7. Belyakov IM, Ahlers JD, Berzofsky JA. Mucosal AIDS vaccines: current status and future directions. Expert Rev Vaccines. 2004;3(suppl):65-73.
8. Belyakov IM, Hel Z, Kelsall B, et al. Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat Med. 2001;7:1320-1326.
9. Belyakov IM, Berzofsky JA. Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines. Immunity. 2004;20:247-253.
10. + lymphocytes. Science. 1999;283:857-860.
11. + T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med. 1999;189:991-998.
12. + cell depletion or CMV infection. Clin Immunol Immunopathol. 1992;65:227-233.
13. Spira AI, Marx PA, Patterson BK, et al. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J Exp Med. 1996;183:215-225.
14. Alexander-Miller MA, Leggatt GR, Berzofsky JA. Selective expansion of high or low avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci U S A. 1996;93:4102-4107.
15. Gallimore A, Dumrese T, Hengartner H, Zinkernagel RM, Rammensee HG. Protective immunity does not correlate with the hierarchy of virusspecific cytotoxic T cell responses to naturally processed peptides. J Exp Med. 1998;187:1647-1657.
16. Derby MA, Alexander-Miller MA, Tse R, Berzofsky JA. High avidity CTL exploit 2 complementary mechanisms to provide better protection against viral infection than low avidity CTL. J Immunol. 2001;166:1690-1697.
17. Snyder JT, Alexander-Miller MA, Berzofsky JA, Belyakov IM. Molecular mechanisms and biological significance of CTL avidity. Curr HIV Res. 2003;1:287-294.
18. O'Connor DH, Allen TM, Vogel TU, et al. Acute phase cytotoxic T lymphocyte escape is a hall-mark of simian immunodeficiency virus infection. Nat Med. 2002;8:493-499.
19. Knapp LA, Lehmann E, Piekarczyk MS, Urvater JA, Watkins DI. A high frequency of Mamu-A*01 in the rhesus macaque detected by polymerase chain reaction with sequence-specific primers and direct sequencing. Tissue Antigens. 1997;50:657-661.
20. Berzofsky JA, Pendleton CD, Clerici M, et al. Construction of peptides encompassing multi-determinant clusters of HIV envelope to induce in vitro T-cell responses in mice and humans of multiple MHC types. J Clin Invest. 1991;88:876-884.
21. Kuroda MJ, Schmitz JE, Barouch DH, et al. Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex. J Exp Med. 1998;187:1373-1381.
22. Allen TM, Mothe BR, Sidney J, et al. CD8(+) lymphocytes from simian immunodeficiency virusinfected rhesus macaques recognize 14 different epitopes bound by the major histocompatibility complex class I molecule mamu-A*01: implications for vaccine design and testing. J Virol. 2000;75:738-749.
23. Tartaglia J, Perkus ME, Taylor J, et al. NYVAC: a highly attenuated strain of vaccinia virus. Virology. 1992;188:217-232.
24. + T cells and AIDS in pigtailed macaques. J Virol. 1996;70:3189-3197.
25. Belyakov IM, Wyatt LS, Ahlers JD, et al. Induction of mucosal CTL response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing HIV 89.6 envelope protein. J Virol. 1998;72:8264-8272.
26. Belyakov IM, Moss B, Strober W, Berzofsky JA. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proc Natl Acad Sci U S A. 1999;96:4512-4517.
27. Altman JD, Moss PAH, Goulder PJR, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996;274:94-96.
28. Romano JW, Shurtliff RN, Dobratz E, et al. Quantitative evaluation of simian immunodeficiency virus infection using NASBA technology. J Virol Methods. 2000;86:61-70.
29. Pal R, Venzon D, Letvin NL, et al. ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. J Virol. 2002;76:292-302.
30. Kuznetsov VA, Stepanov VS, Berzofsky JA, Belyakov IM. Assessment of the relative therapeutic effects of vaccines on virus load and immune responses in small groups at several time points: An efficacy of mucosal and subcutaneous polypeptide vaccines in rhesus macaques exposed to SHIV. J Clin Virol. 2004:S69-S82.
31. Belyakov IM, Earl P, Dzutsev A, et al. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc Natl Acad Sci U S A. 2003;100:9458-9463.
32. Allen TM, Sidney J, Del Guercio MF, et al. Characterization of the peptide binding motif of a rhesus MHC class I molecule (Mamu-A*01) that binds an immunodominant CTL epitope from simian immunodeficiency virus. J Immunol. 1998;160:6062-6071.
33. Ahlers JD, Dunlop N, Alling DW, Nara PL, Berzofsky JA. Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: GM-CSF and TNFa synergize with IL-12 to enhance induction of CTL. J Immunol. 1997;158:3947-3958.
34. O'Neill E, Martinez I, Villinger F, et al. Protection by SIV VLP DNA prime/protein boost following mucosal SIV challenge is markedly enhanced by IL-12/GM-CSF co-administration. J Med Primatol. 2002;31:217-227.
35. Ahlers JD, Belyakov IM, Berzofsky JA. Cytokine, chemokine and costimulatory molecule modulation to enhance efficacy of HIV vaccines. Curr Mol Med. 2003;3:285-301.
36. Belyakov IM, Ahlers JD, Clements JD, Strober W, Berzofsky JA. Interplay of cytokines and adjuvants in the regulation of mucosal and systemic HIV-specific cytotoxic T lymphocytes. J Immunol. 2000;165:6454-6462.
37. Verthelyi D, Kenney RT, Seder RA, Gam AA, Friedag B, Klinman DM. CpG oligodeoxynucleotides as vaccine adjuvants in primates. J Immunol. 2002;168:1659-1663.
38. Ahlers JD, Belyakov IM, Terabe M, et al. A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with GM-CSF and CD40L. Proc Natl Acad Sci U S A. 2002;99:13020-13025.
39. Hanke T, Blanchard TJ, Schneider J, et al. Enhancement of MHC class I-restricted peptidespecific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine. 1998;16:439-445.
40. Amara RR, Villinger F, Altman JD, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science. 2001;292:69-74.
41. Shiver JW, Fu TM, Chen L, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 2002;415:331-335.
42. ++ T cell responses. J Immunol. 2002;169:4778-4787.
43. Stevceva L, Alvarez X, Lackner AA, et al. Both mucosal and systemic routes of immunization with the live, attenuated NYVAC/simian immunodeficiency virus SIV(gpe) recombinant vaccine result in gag-specific CD8(+) T-cell responses in mucosal tissues of macaques. J Virol. 2002;76:11659-11676.
44. Belyakov IM, Wang J, Koka R, et al. Activating CTL precursors to reveal CTL function without skewing the repertoire by in vitro expansion. Eur J Immunol. 2001;31:3557-3566.
45. Berzofsky JA, Ahlers JD, Derby MA, Pendleton CD, Arichi T, Belyakov IM. Approaches to improve engineered vaccines for human immunodeficiency virus (HIV) and other viruses that cause chronic infections. Immunol Rev. 1999;170:151-172.
46. Berzofsky JA, Ahlers J, Janik J, et al. Progress on new vaccine strategies against chronic viral infections. J Clin Invest. 2004;114:450-462.
47. Berzofsky JA, Ahlers JD, Belyakov IM. Strategies for designing and optimizing new generation vaccines. Nat Rev Immunol. 2001;1:209-219.
48. Belyakov IM, Hammond SA, Ahlers JD, Glenn GM, Berzofsky JA. Transcutaneous immunization induces mucosal CTL and protective immunity by migration of primed skin dendritic cells. J Clin Invest. 2004;113:998-1007.
49. Lehner T, Bergmeier L, Wang Y, Tao L, Mitchell E. A rational basis for mucosal vaccination against HIV infection. Immunol Rev. 1999;170:183-196.
50. Murphey-Corb M, Wilson LA, Trichel AM, et al. Selective induction of protective MHC class I restricted CTL in the intestinal lamina propria of rhesus monkeys by transient SIV infection of the colonic mucosa. J Immunol. 1999;162:540-549.
51. + T-cell approach feasible? Nat Rev Immunol. 2002;2:283-291.
52. Calarota SA, Weiner DB. Present status of human HIV vaccine development. AIDS. 2003;17(suppl 4):S73-S84.
53. Johnson RP, Lifson JD, Czajak SC, et al. Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. J Virol. 1999;73:4952-4961.
54. Lohman BL, Miller CJ, McChesney MB. Antiviral cytotoxic T lymphocytes in vaginal mucosa of simian immunodeficiency virus-infected rhesus macaques. J Immunol. 1995;155:5855-5860.
55. Oh S, Hodge JW, Ahlers JD, Burke DS, Schlom J, Berzofsky JA. Selective induction of high avidity CTL by altering the balance of signals from antigen presenting cells. J Immunol. 2003;170:2523-2530.
56. +T cells. Proc Natl Acad Sci U S A. 2004;101:15154-15159.